InsideTracker was started at MIT by a scientist named Gil Blander, who wanted to know whether aging was a plumbing problem that could be measured. Sellam is the non-scientist half of the partnership. His job, as he has described it in more than one interview, is to turn Blander's laboratory into something you can buy on shopify.com and not regret in two weeks. He is also the person answering board questions about churn, so the pairing is doing something.
Before Cambridge, Sellam was a Deloitte consultant in Geneva. He speaks about that period the way many consultants do about their consulting era: as the fork in the road. Deloitte's Global Development Program is a rotation that sends people abroad for a year and a half or two. It sent Sellam to Boston. He liked Boston enough to stop coming back to Geneva. He liked it because of the "innovation ecosystem," a phrase that gets thrown around loosely, but in his case seems to have been literal: within a short window he was hired away from Deloitte by a client, which he notes is what happens all the time in consulting and nobody minds.
The cardiologist conversation
Every founder story has an origin conversation. Sellam's is with Dr. Spencer King, a cardiologist he encountered in his healthcare-IT years. The paraphrased line is that if King could redo his career he would spend it on prevention, not intervention. Sellam took it seriously enough to spend the next decade-plus building a consumer product for prevention. The point is not that Sellam invented preventive medicine; the point is that a consultant is unusually good at translating a cardiologist's regret into a product roadmap.
For years the consumer-longevity idea sounded speculative. Longevity was a bearded man on Twitter with a lipid panel. Then something shifted. In 2024 Sellam noted, gently, that "a few years ago, when we talked about healthspan and longevity, people called us crazy." The gentleness was the tell. He had been running the same company saying the same things for over a decade, and one day the language he was already using became mainstream. That is a form of luck, and it is also a form of stamina.
The number he keeps citing
There is a statistic that Sellam returns to in interviews: in the United States, there is roughly a sixteen-year gap between how long people live and how long they live well. He uses it the way a founder uses a large addressable market slide. It is also, of course, the actual reason to build a healthspan company. The gap is real. It exists whether or not InsideTracker exists. Sellam's argument is that most of it is not addressed by a doctor's visit that begins after something has gone wrong. It is addressed, if at all, by information you have about yourself while things are still going right.
The bleed-on-your-iPhone hypothesis
Sellam has one prediction he repeats and it is memorable enough to be repeated back to him. He thinks the walk-into-a-lab step will disappear. Bleeding, peeing, or sweating on a phone-adjacent device will produce a real-time result. He does not claim InsideTracker will be the company that ships the device. He is claiming that InsideTracker's software layer, the recommendation engine, is the part that survives regardless of who wins the hardware race. Whether this is optimism or product positioning depends on how the next few years go. He has been right about roughly the right amount of things.
The scientist and the operator
Gil Blander's name is on the science. Sellam's name is on the P&L. This division of labor is not novel in biotech - scientist founder pairs with commercial CEO happens every quarter in Cambridge - but the two of them have talked about it publicly on the Authentic Leadership podcast, which is unusual. Founder/CEO relationships are usually described only after they have gone badly. Sellam and Blander have kept theirs intact through a Series B and a category shift. That is, quietly, the operating story of InsideTracker.
The company sits at 53 employees per public estimates and serves north of 100,000 members. If both numbers are approximately correct, InsideTracker has about 1,900 members per employee, which is either a compliment to the software or a warning about the operations. Sellam's job, most days, is on the operations side of that ratio.
Personalization, in italics
The first InsideTracker interview available online is from 2014, in a nutrition trade publication. In it, Sellam says the one-size-fits-all intervention approach makes no sense and that personalization is the future. Ten years later he says roughly the same thing in slightly better English. There are two ways to interpret this. One: he has been unable to develop a new message. Two: he was correct in 2014 and the market took a decade to catch up. The trade press has slowly come around to the latter reading. Personalized nutrition is now a category. InsideTracker was there before it was a category.
What still separates the company, in his telling, is that recommendations are tied to peer-reviewed literature. This is not a claim you can make in an ad. It is a claim you make when someone with a lab coat asks you why they should trust the app. In the wellness market, most competitors have chosen the other side of that trade. Sellam has chosen the scientist's answer, which is why the scientist has stayed.
Boston, kept
He was supposed to be in the U.S. for eighteen months. He and his wife decided to stay. Cambridge got him, first through Deloitte's client roster and then through an MIT scientist who wanted a commercial partner. There is a version of Sellam's career that stays in Geneva, does not meet Blander, does not run a consumer-longevity company. It is not a version he seems to spend time on.